Larvol Delta - BioAtla-Presents-Compelling-Mechanistic-Rationale-for-Targeting-ROR2-with-Ozuriftamab-Vedotin-OzV-in-Oropharyngeal-Squamous-Cell-Carcinoma-OPSCC-at-the-Annual-Conference-of-the-International-Papillomavirus-Society

ozuriftamab vedotin (BA3021) - BioAtla

https://www.globenewswire.com/news-release/2025/10/23/3172001/0/en/BioAtla-Presents-Compelling-Mechanistic-Rationale-for-Targeting-ROR2-with-Ozuriftamab-Vedotin-Oz-V-in-Oropharyngeal-Squamous-Cell-Carcinoma-OPSCC-at-the-Annual-Conference-of-the-In.html

Oct 23, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next